Factors Influencing Treatment Satisfaction and Recognition Gaps Between Physicians and Patients with Systemic Sclerosis

Overview

Journal Rheumatol Ther

Date 2025 Feb 5

PMID 39907912

Authors

Yoshihito Shima

Mona Uchida-Yamada

Sei-Ichiro Motegi

Taku Shimada

Haruka Ishii

Yoshito Ohya

Yasumasa Kanai

Affiliations

Soon will be listed here.

Abstract

Introduction: It is important to understand the differences in patient-physician perceptions and factors affecting satisfaction with treatment in patients with systemic sclerosis (SSc).

Methods: This web-based survey (conducted in Japan in March 2023) targeted patients aged ≥ 18 years with SSc and physicians in hospitals with ≥ 20 beds and seeing ≥ 3 patients with SSc monthly. Physicians and patients answered similar questions.

Results: Responders were 301 patients (63.8% female; 47.5% limited cutaneous SSc; 44.9% diffuse cutaneous SSc) and 129 physicians (51.2% rheumatologists; 20.9% dermatologists). The most common problematic symptoms reported by patients having each symptom were Raynaud's phenomenon (RP) (59.5%), skin tightening (47.4%), and malaise (45.5%). Physicians also perceived RP as the common problematic symptoms (46.5%). Conversely, there was a large gap in the perception of malaise as problematic (5.4%). There was a ≥ 20% difference in the percentage of respondents who felt that treatments improved symptoms of reflux esophagitis (48.8% in patients vs. 76.7% in physicians), dysphagia (25.0% vs. 52.7%), constipation (35.1% vs. 62.8%), diarrhea (36.1% vs. 62.8%), and pain (47.6% vs. 69.0%). Patient characteristics associated with high satisfaction with treatment included treatment responsiveness, age ≥ 50 years, being anti-topoisomerase I antibody positive, having dermatological or digestive symptoms as problematic symptoms, and not feeling they should have seen their physician earlier.

Conclusions: Patients and physicians had different perceptions of symptoms and treatment response. Patients' perception of improvement affected their satisfaction with treatment. Reviewing treatment goals and content between patients and physicians is necessary to improve treatment satisfaction.

Trial Registration: UMIN000050368.

References

Denton C, Khanna D . Systemic sclerosis. Lancet. 2017; 390(10103):1685-1699. DOI: 10.1016/S0140-6736(17)30933-9. View

Di Battista M, Lepri G, Codullo V, Da Rio M, Fiorentini E, Della Rossa A . Systemic sclerosis: one year in review 2023. Clin Exp Rheumatol. 2023; 41(8):1567-1574. DOI: 10.55563/clinexprheumatol/ki76s5. View

Smith V, Scire C, Talarico R, Airo P, Alexander T, Allanore Y . Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open. 2018; 4(Suppl 1):e000782. PMC: 6203100. DOI: 10.1136/rmdopen-2018-000782. View

Arat S, Lenaerts J, De Langhe E, Verschueren P, Moons P, Vandenberghe J . Illness representations of systemic lupus erythematosus and systemic sclerosis: a comparison of patients, their rheumatologists and their general practitioners. Lupus Sci Med. 2017; 4(1):e000232. PMC: 5687554. DOI: 10.1136/lupus-2017-000232. View

Mouthon L, Alami S, Boisard A, Chaigne B, Hachulla E, Poiraudeau S . Patients' views and needs about systemic sclerosis and its management: a qualitative interview study. BMC Musculoskelet Disord. 2017; 18(1):230. PMC: 5450385. DOI: 10.1186/s12891-017-1603-4. View

Cossu M, Beretta L, Mosterman P, de Hair M, Radstake T . Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective. Clin Rev Allergy Immunol. 2017; 55(3):312-331. PMC: 6244948. DOI: 10.1007/s12016-017-8636-1. View

Denton C, Laird B, Moros L, Luna Flores J . Things left unsaid: important topics that are not discussed between patients with systemic sclerosis, their carers and their healthcare professionals-a discourse analysis. Clin Rheumatol. 2020; 40(4):1399-1407. PMC: 7943486. DOI: 10.1007/s10067-020-05371-2. View

Thoreau B, Chaigne B, Renaud A, Mouthon L . Treatment of systemic sclerosis. Presse Med. 2021; 50(1):104088. DOI: 10.1016/j.lpm.2021.104088. View

Bassel M, Hudson M, Taillefer S, Schieir O, Baron M, Thombs B . Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology (Oxford). 2010; 50(4):762-7. DOI: 10.1093/rheumatology/keq310. View

10.

Harb S, Pelaez S, Carrier M, Kwakkenbos L, Bartlett S, Hudson M . Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient-Centered Intervention Network Cohort Study. Arthritis Care Res (Hoboken). 2021; 74(8):1300-1310. DOI: 10.1002/acr.24567. View

11.

Nagaraja V, Matucci-Cerinic M, Furst D, Kuwana M, Allanore Y, Denton C . Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. Arthritis Rheumatol. 2020; 72(7):1049-1058. PMC: 7329619. DOI: 10.1002/art.41246. View

12.

Young A, Namas R, Dodge C, Khanna D . Hand Impairment in Systemic Sclerosis: Various Manifestations and Currently Available Treatment. Curr Treatm Opt Rheumatol. 2016; 2(3):252-269. PMC: 5176259. DOI: 10.1007/s40674-016-0052-9. View

13.

Sandler R, Matucci-Cerinic M, Hughes M . Musculoskeletal hand involvement in systemic sclerosis. Semin Arthritis Rheum. 2019; 50(2):329-334. DOI: 10.1016/j.semarthrit.2019.11.003. View

14.

Horsley-Silva J, Umar S, Vela M, Griffing W, Parish J, DiBaise J . The impact of gastroesophageal reflux disease symptoms in scleroderma: effects on sleep quality. Dis Esophagus. 2019; 32(5). DOI: 10.1093/dote/doy136. View

15.

Shah J, Shahidullah A . Chronic Intestinal Pseudo-Obstruction in Systemic Sclerosis: An Uncommon Presentation. Case Rep Gastroenterol. 2018; 12(2):373-378. PMC: 6062715. DOI: 10.1159/000490526. View

16.

Yakut H, Ozalevli S, Birlik A . Fatigue and its relationship with disease-related factors in patients with systemic sclerosis: A cross-sectional study. Turk J Med Sci. 2020; 51(2):530-539. PMC: 8203131. DOI: 10.3906/sag-2005-314. View

17.

Cheema T, Young M, Rabold E, Barbieri A, Baldwin N, Steen V . Patient and Physician Perspectives on Systemic Sclerosis-Associated Interstitial Lung Disease. Clin Med Insights Circ Respir Pulm Med. 2020; 14:1179548420913281. PMC: 7081464. DOI: 10.1177/1179548420913281. View

18.

Saketkoo L, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K . Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. J Rheumatol. 2014; 41(4):792-8. PMC: 4369780. DOI: 10.3899/jrheum.131251. View

19.

Denton C, De Lorenzis E, Roblin E, Goldman N, Alcacer-Pitarch B, Blamont E . The 2024 British Society for Rheumatology guideline for management of systemic sclerosis. Rheumatology (Oxford). 2024; 63(11):2956-2975. PMC: 11534099. DOI: 10.1093/rheumatology/keae394. View

20.

Pakozdi A, Howell K, Wilson H, Fox S, Gonzalez L, Black C . Inhaled iloprost for the treatment of Raynaud's phenomenon. Clin Exp Rheumatol. 2008; 26(4):709. View